Federal Supply Schedule 36F79719D0163
Award Date
6/1/19
Last Date to Order
5/31/24
Federal Agency
Veterans Integrated Service Network 12
Awardee
Insmed Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
Insmed Inc., a global biopharmaceutical company, holds a Multiple Award Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) under Schedule 65 IB, Drugs, Pharmaceuticals, & Hematology Related Products. Under this $24.15 million IDV with a period of performance through May 2029, Insmed provides critical pharmaceutical products to the VA, including the antibiotic amikacin and the liposomal amikacin inhalation medication ARIKAYCE. Insmed also holds a...
This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Insmed Inc., a global biopharmaceutical company specializing in rare respiratory diseases. The contract, valued at $49,323.45, provides for the delivery of the pharmaceutical product ARIKAYCE, a liposomal amikacin inhalation medication used to treat nontuberculous mycobacterial lung infections. This single-award BPA allows the VA to issue task orders...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The Department of Veterans Affairs (VA) has awarded Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies, an IDV Federal Supply Schedule contract (36F79723D0194) valued at over $16.3 million. This multiple-award contract covers the procurement of drugs, pharmaceuticals, and hematology-related products through September 2028. Under this IDV, the VA Veterans Integrated Service Network 12 has issued firm fixed-price delivery orders for Acorda's Levodopa 42mg...
The Department of Veterans Affairs (VA) has awarded Amivas US LLC a five-year, $225,000 multiple-award Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs schedule (FSS-61-IB). This IDV allows VA medical facilities to issue task orders for Amivas' pharmaceuticals and hematology-related products. Amivas, a for-profit limited liability company, has prior experience providing pharmaceuticals and services related to clinical trials and medical research for federal agencies....
The U.S. Department of Veterans Affairs (VA) has awarded a $198 million Federal Supply Schedule (FSS) contract and a $50 million Blanket Purchase Agreement (BPA) to United Therapeutics Corporation, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods. These Indefinite Delivery Vehicles (IDVs) allow the VA to efficiently procure United Therapeutics' specialized drug portfolio, including treatments for pulmonary arterial hypertension and certain types of cancer,...
The U.S. Department of Veterans Affairs (VA) awarded Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer, a $15.6 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.1 million single-award Blanket Purchase Agreement to supply specialized orphan drugs and rare disease treatments. The contract vehicles allow the VA to efficiently procure Recordati's portfolio of medications, including Signifor LAR, Carbaglu, Cystadane, Isturisa, and Cystadrops,...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Acorda Therapeutics, Inc. for the procurement of Inbrija and Ampyra. The contract has a potential value of $7.5 million and a period of performance through January 2024. The contract was awarded off the Pharmaceuticals and Drugs Federal Supply Schedule and provides a single award vehicle for ordering Inbrija, a treatment for off episodes related to Parkinson's disease, and Ampyra, a...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 to Amarin Pharma, Inc. as a multiple award against the Pharmaceuticals and Drugs schedule. The contract aims to procure drugs, pharmaceuticals, and hematology related products over a potential value of $4 million through February 2024. The contract provides access to Amarin Corporation P L C's portfolio of products through the Federal...
The Department of Veterans Affairs (VA) awarded a single-award Blanket Purchase Agreement (BPA) to Recordati Rare Diseases Inc., a division of the Recordati Group, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The $3,156,115.00 BPA covers a period of performance from July 2021 to July 2025 and allows the VA to efficiently procure a range of Recordati's specialized orphan drugs, including Signifor, Carbaglu, Cystadane, Isturisa, and Cystadrops. These medications are...